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Atherosclerosis is a chronic inflammatory disease that is mediated by both the innate and adaptive immune responses. T
lymphocytes, that together with B cells are the cellular eﬀectors of the adaptive immune system, are currently endowed with
crucial roles in the development and progression of atherosclerosis. Costimulatory receptors are a class of molecules expressed
by T lymphocytes that regulate the activation of T cells and the generation of eﬀector T-cell responses. In this review we present
the roles of costimulatory receptors of the tumour necrosis factor receptor (TNFR) superfamily in atherosclerosis and discuss the
implications for future therapies that could be used to specifically modulate the immune response of pathogenic T cells in this
disease.
1. Introduction
Atherosclerosis is a disease of large and medium-sized arter-
ies, characterized by focal thickening of the innermost layer
of the arterial wall, the intima, due to accumulation of lipids.
Initially, it was thought that the main pathogenic mechanism
was deposition of lipids (mainly low density lipoprotein,
LDL) in the vessel wall. However, evidence from several stud-
ies on animal models and the human disease showed that
atherosclerosis is predominantly a chronic inflammatory dis-
order that involves various cells of the innate and adaptive
arms of the immune system (reviewed in [1, 2]). The first
insight on the contribution of the adaptive immune system
to atherogenesis that was at the timemainly regarded as a dis-
ease mediated exclusively by innate immune cells such as
macrophages, came with the identification of T cells in
human atherosclerotic plaques [3, 4]. Moreover, detection
of T-cell-dependent antibodies directed against oxidised LDL
(oxLDL) in patients with atherosclerosis [5] provided further
support to the view that T cells actively mediate atherogene-
sis. It is now well accepted that the main cellular components
of the adaptive immune system, T and B lymphocytes, have
important eﬀects not only on the development of atheroscle-
rotic plaques but also in the processes that lead to plaque
rupture [6].
T-cell-mediated adaptive immune responses are trig-
gered by recognition of antigen (derived from pathogens) on
antigen presenting cells (APCs) such as dendritic cells (DCs)
and macrophages. However, optimal activation of T cells and
generation of eﬀector/memory responses requires more than
just antigen recognition and is tightly dependent on costimu-
latory signals. These are delivered by costimulatory receptors
expressed on T lymphocytes following interaction with their
ligands on APCs [7]. The expression of costimulatory ligands
on APCs is often triggered or upregulated by infection or cell
damage and therefore is designed to elicit immune responses
only when required, limiting the chance for unwanted re-
sponses. Due to their central roles in modulation of T-cell
responses, costimulatory receptors and their ligands repre-
sent a promising target for the treatment of diseases associat-
ed with chronic inflammation (autoimmunity, organ trans-
plantation, and cancer). Currently, a great deal of eﬀort is
concentrated on designing therapeutic tools (neutralising
antibodies, agonistic antibodies, immunoglobulin fusion
proteins, etc.) that will enable targeted manipulation of
costimulatory pathways in pathogenic T cells. A family of
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costimulatory receptors that has captured the attention of the
scientific community as a particularly promising target for
immunemodulation is the tumour necrosis factor receptor
(TNFR) superfamily. Several members of this family with
costimulatory function have been shown to contribute to the
immune response underlying atherosclerosis. Here, we dis-
cuss the roles of TNFR costimulatory receptors in atheroscle-
rosis and highlight therapeutic strategies to modulate these
molecules that could soon find their way into the clinic
to tackle this disease.
2. T Cells in Atherosclerosis
In addition to the key roles played by cells of the innate im-
mune system (i.e., macrophages, dendritic cells (DCs), mast
cells, and neutrophils) in atherogenesis (recently reviewed
[1, 8]), T and B lymphocytes, which are the main mediators
of adaptive immunity, have also important contributions [9].
Indeed, T cells have been consistently found in atheroscle-
rotic lesions, accounting for almost 20% of the cells in the
shoulder region of a plaque, and activated T cells are signif-
icantly increased in culprit lesions of patients with acute cor-
onary syndrome (ACS) [3, 4]. Furthermore, T cells from
atherosclerotic plaques were shown to have an activated phe-
notype [10, 11] and to be involved in all stages of atherogene-
sis [12]. The current view is that T cells aggravate atheroscle-
rosis by triggering inflammatory immune responses and con-
tribute to the growth and rupture of atherosclerotic plaques.
A large number of studies on animal models that
provide mechanistic insight in atherogenesis have shown
that CD4+ T cells, and to a lesser extent CD8+ T cells,
have active roles in this disease [13]. Indeed, the majority
of T cells present in atherosclerotic plaques are CD4+ T
cells [14]. Moreover, an elegant study performed by Zhou
and colleagues demonstrated that the adoptive transfer of
CD4+ T cells in Apoe−/− mice had proatherogenic eﬀects
[15]. While the role of CD4+ T cells in atherogenesis and
plaque destabilization is now widely accepted, the complex
dynamics of the diﬀerent CD4+ T cells subsets and their con-
tribution to atherogenesis is far from being understood. The
main subsets of CD4+ T cells consist of T helper 1 (Th1)
identified by their ability to secrete the proinflammatory
cytokine interferon-γ (IFN-γ); Th2 cells that produce mainly
interleukin-4 (IL-4); Th17 cells with IL-17 as their signature
cytokine; regulatory T (Treg) cells that have important roles
in suppression of immune responses and tolerance. Th1
cells have mainly proatherogenic eﬀects, while the Th2 and
Treg cell subsets have protective roles in atherosclerosis (re-
viewed in [9]). The contribution of the Th17 subset is not
clear, as controversial results have suggested both pro- and
antiatherogenic roles [16–18]. It is also possible that each T-
cell subset and their products (i.e., cytokines) have diﬀerent
roles depending on the stage of atherosclerosis.
Several lines of evidence suggest that T cells are activated
in atherosclerosis [10, 11], however the precise mechanisms
responsible for this phenomenon remain largely unknown.
The antigens that trigger the activation and expansion of T
cells in atherosclerosis have not been fully characterized so
far. Various infectious agents have been implicated as T cells
that recognise antigens derived fromChlamydia pneumoniae,
Herpes simplex,Helicobacter pylori, andCytomegalovirus have
been identified in the atherosclerotic lesions and peripheral
circulation of patients with atherosclerosis [19]. In addition
to these exogenous triggers, antigens from endogenous
sources (such as oxLDL and human heat shock proteins,
HSPs) have also been described in atherosclerosis [20, 21].
The expression of these antigens is very prominent in athero-
sclerotic lesions and correlates with the severity of the disease
[22, 23]. Another aspect of the immune response in athero-
sclerosis that is not completely understood is the site of anti-
gen presentation and lymphocyte activation, which could
either take place locally in the plaque or in the regional lymph
nodes [3]. A study done by Rekhter and Gordon found that
T cells proliferate in the atherosclerotic plaques, while a
similar expansion could not be detected in the peripheral
circulating compartment, suggesting a localized immune
response within the plaques where recruitment, local activa-
tion, and generation of eﬀector and memory T cells takes
place [11]. Moreover, both antigen-dependent and antigen-
independent (e.g., coreceptors and cytokines like IL-7 and
IL-15) pathways may contribute to oligoclonal expansion of
T cells in atherosclerotic plaques [24]. All these uncertainties
regarding the antigens that elicit and drive the immune
response in atherosclerosis hinder the design of therapeutic
protocols that could slow down the progression of this
disease. As costimulatory signals are crucial for the activation
of T cells (either in the naive or eﬀector/memory stage) and
the function of eﬀector T lymphocytes, modulation of cos-
timulatory pathways could provide an alternative strategy to
modulate the immune response in atherosclerosis.
3. Effects of Costimulation in T Cells
As mentioned in the introduction, T-cell activation is trig-
gered by antigen recognition on APC (e.g., DCs and macro-
phages). This process takes place in the secondary lymphoid
organs (lymph nodes or spleen) and leads to the activation
of T lymphocytes and their proliferation and diﬀerentiation
into eﬀector T cells. Some of these eﬀector T cells will migrate
into the inflamed/infected tissues and tackle the pathogens
themselves or deliver signals required for the activation of
macrophages (and other cells of the innate immune system)
so that they can eﬃciently clear the infection. In addition,
certain subsets of eﬀector T cells deliver signals that direct the
production of antibodies by B cells. A small population of
memory T cells are also induced following antigen recogni-
tion, and these cells are responsible for the quick and eﬀective
clearance of pathogens following subsequent contact with
the same pathogen (i.e., recall immune responses). In the
case of naive T cells, antigen recognition is not suﬃcient for
the activation of T cells, and a second signal, called the cos-
timulatory signal, is required [7]. This second signal is
delivered following interaction of costimulatory receptors
expressed on T cells with their ligands (i.e., costimulatory
molecules) expressed on APCs. Costimulation is neither
antigen specific nor MHC dependent and is involved in the
bidirectional signalling in and out of T cells [7]. Costim-
ulatory signals are critical to allow full activation of naive
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T cells and their diﬀerentiation into eﬀector and/or memory
T cells. Moreover, Costimulation is critical for the survival
of T cells by preventing apoptosis and/or anergy and for the
production of cytokines by eﬀector T lymphocytes [7]. In
addition, cooperation between T cells and other cells of the
immune system (such as B lymphocytes, DCs, and macro-
phages) is also tightly regulated by interaction between
costimulatory receptors and ligands [25]. In addition to
costimulatory signals, the diﬀerentiation of CD4+ T lympho-
cytes into various eﬀector cells is regulated by cytokines
present in the microenvironment at the moment of T-cell
activation (i.e., signal three). The generation of Th1 cells
is controlled by IL-12 that is secreted by mature DCs and
activated macrophages upon interaction with microbial
products [26]. IL-4 is the main cytokine that drives diﬀere-
ntiation into the Th2 lineage [27]. With regard to the cyto-
kines that regulate the generation of Th17 cells some debate
still exists, with IL-6 being a definite requirement, while
the contribution of transforming growth factor-β (TGF-β)
has been questioned by some studies [28–30]. Some of the
cytokines that deliver signal three for eﬀector T-cell diﬀeren-
tiation have been implicated in atherosclerosis (recently re-
viewed in [31]).
The first identified costimulatory receptor is CD28 that
is constitutively expressed on naive T cells and promotes
T-cell activation [7]. In the absence of signals via CD28,
naive T cells fail to get activated and enter a state of aner-
gy. Engagement of CD28 by its ligands B7.1 (CD80) and B7.2
(CD86) lowers the activation threshold of T cells and pro-
vides key stimulatory signals to allow high-level IL-2 produc-
tion and survival of naive T cells [32]. Activated T cells ex-
press additional costimulatory receptors to CD28, some of
which sustain T-cell activation (e.g., ICOS, inducible co-
stimulator; OX40; 4-1BB), and others, with inhibitory eﬀects
(e.g., CTLA-4, cytotoxic T lymphocyte antigen-4; and PD-1,
programmed death-1) [32–35]. The coinhibitory receptors
have critical roles in limiting the activation and expansion
of T cells and prevent the development of pathological im-
mune responses by induction and maintenance of T-cell tol-
erance [36]. An optimal balance between costimulatory and
coinhibitory receptors is critical for an adequate and well-
balanced T-cell response following encounter with patho-
gens. Based on their structure, costimulatory receptors have
been grouped in two main families: the immunoglobulin
(Ig) superfamily (which includes CD28, CTLA-4, and PD-1)
and the tumour necrosis factor receptor (TNFR) family, in-
cluding OX40, 4-1BB, and others, which will be discussed in
the next section.
4. Costimulatory Receptors of the TNFR Family
TNFR/TNF ligand superfamily has several members that
are involved in Costimulation of T cells: CD40/CD40L,
OX40/OX40L, 4-1BB/4-1BBL, CD27/CD70, CD30/CD30L,
HVEM/LIGHT, and GITR/GITRL [35, 37]. In contrast to
CD28, which is constitutively expressed by naive T cells,
the expression of most of the costimulatory receptors of
TNFR family is only induced following T-cell activation,
hours to days after antigen recognition [25]. These receptors
provide signals that promote the expansion and survival of T
cells to amplify and sustain the longevity of T-cell-mediat-
ed immune responses and to enhance the generation of
eﬀector and memory T cells both in primary and recall im-
mune responses [25]. In addition, signals via TNFR costim-
ulatory receptors increase the production of cytokines by
eﬀector T cells. The majority of TNFR costimulatory recep-
tors lack intrinsic signalling activity and thereby need to
recruit intracellular adaptor molecules called TNFR-associ-
ated factors (TRAFs) to trigger intracellular signalling path-
ways [35]. Six mammalian TRAF proteins have been iden-
tified so far (TRAF1-6), which have been shown to interact
directly or indirectly with the intracellular domains of the
TNFR [38]. TRAF proteins have a conserved 180 amino acid
fold, the TRAF domain (TD), which promotes the intera-
ction between TNFRs and their downstream signalling inter-
mediates. The C-terminus of the TD mediates homo- and
heterodimerization with other TRAF proteins and the recep-
tor that recruits them. The cytosolic region of TNFR contains
motifs 4–6 amino acids long that regulate the interaction
with TRAFs [39]. TNFR ligation leads to TRAF aggregation
and subsequent activation of downstream protein kinase cas-
cades. Several TRAFs can trigger the activation of nuclear
factor-κB (NF-κB) by interacting with the inhibitor of NF-κB
(IκB) subunits [40]. NF-κB signalling promotes cell survival
by regulation of apoptosis pathways. Costimulatory signals
delivered by TNF/TRAF interactions promote the prolifera-
tion of T cells by enabling progression through the cell cycle
[41]. In addition, TRAF members activate mitogen-activated
protein (MAP) kinase signalling that is important for the
production of proinflammatory cytokines by T lymphocytes
[42]. It is likely that structural diﬀerences between various
TRAF members determine the signalling pathways that will
be triggered and the ultimate cellular eﬀects [35]. We next
discuss the contribution of various TNFR costimulatory re-
ceptors to atherosclerosis.
5. CD40 and CD40L
CD40L (also known as CD154) was originally identified on
activated T cells, while CD40 is expressed by APCs [43,
44] (Table 1). Costimulatory signals delivered by the CD40/
CD40L pair are crucial for optimal APC activation and pro-
duction of inflammatory cytokines. In addition, they also
promote the activation of T cells by increasing the expression
of costimulatory ligands on APCs [43, 44]. Furthermore, as
B cells constitutively express CD40, interaction with CD40L
on activated T cells is crucial for the development of humoral
immune responses regulating the proliferation of B lympho-
cytes and the production of antibodies, isotype switching,
and generation of memory B cells [45]. In addition to
these roles in regulation of adaptive immune responses and
inflammation, CD40/CD40L interaction enhances angiogen-
esis. CD40 ligation with soluble CD40L (sCD40L) triggered
production of vascular endothelial growth factor (VEGF)
from endothelial cells and monocytes and promoted angio-
genesis [46]. Another study demonstrated that endothelial
cells treated with anti-CD40L antibodies to ligate CD40 pro-
duced several angiogenic factors (including VEGF and
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Table 1: Expression and key features of costimulatory TNFR family members in T cells.
Receptor/ligand Receptor distribution Ligand distribution Main eﬀects on T cells Ref.
CD40/CD40L
APCs (DCs, B cells,
macrophages)
Activated T cells
Activated DCs
Promotes T-cell activation by increasing costimulatory
ligands on APCs
[43, 44]
OX40/OX40L
Activated T cells
Treg cells
NK cells
NKT cells
Neutrophils
APCs (DCs, B cells,
and macrophages)
Activated T cells
NK cells
Activated endothelial
cells
Smooth muscle cells
Mast cells
Prolongs T-cell clonal expansion
Increases production of cytokines from eﬀector T cells
Promotes the survival of activated T cells
Inhibits the development and suppressive function of
Treg cells (?)
[70, 71]
4-1BB/4-1BBL
Activated T cells
Monocytes
DCs
NK cells
NKT cells
Neutrophils
Endothelial cells
APCs (DCs, B cells,
and macrophages)
Activated T cells
Promotes the activation, survival, and function of
eﬀector T cells
[94]
CD27/CD70
Naive T cells
Thymocytes
Memory B cells
NK cells
APCs (DCs and B
cells)
Activated T cells
Regulates the generation of eﬀector T cells by
enhancing the proliferation and survival of activated T
cells
[118, 119]
CD30/CD30L
Activated T cells
B cells
NK cells
Eosinophils
B cells
Activated T cells
Increases proliferation and cytokine production of T
cells
[128–130]
HVEM/LIGHT
Resting T cells
DCs
Monocytes
Monocytes
Immature DCs
Activated T cells
NK cells
Promotes T-cell activation and cytokine production [134, 135]
GITR/GITRL
Resting and activated
T cells
Constitutive
Expression in Treg
cells
APCs (DCs, B cells,
and macrophages)
Enhances the proliferation and survival of activated T
cells
Potentiates the production of cytokines from eﬀector T
cells
Role in suppressive function of Treg cells
[98, 139, 141,
142]
fibroblast growth factor 2). Furthermore, administration of
CD40L-expressing cells dramatically enhanced angiogenesis
in human skin grafts transplanted in immunodeficient SCID
mice [47]. In addition, the CD40/CD40L system and the
adaptor molecule TRAF6 are also involved in neointima for-
mation and arterial remodelling [48]. These results suggest
that CD40-CD40L interactions have crucial roles in mediat-
ing inflammation and angiogenesis and could therefore con-
tribute to the development and progression of atherosclerotic
plaques.
Several cells within atherosclerotic plaques such as endo-
thelial cells, macrophages, vascular smooth muscle cells, and
T lymphocytes express CD40 and CD40L [49, 50]. Of note,
platelets express CD40 constitutively, and CD40L is induced
on activated platelets [51]. Interaction of CD40L on activated
T cells with CD40 in the plaque microenvironment is
thought to contribute to secretion of inflammatory cytokines
and matrix metalloproteinases from macrophages and to en-
hance the expression of adhesion molecules on endothelial
cells [52]. Further proof that CD40 and CD40L contribute
to atherosclerosis comes from studies that have targeted
these molecules in murine models of the disease (Table 2).
Administration of a neutralising antibody against CD40 to
Ldlr−/− mice reduced the size and lipid content of athero-
sclerotic lesions [53]. In addition, the macrophage and
T-cell infiltrate was dramatically reduced in atherosclerotic
plaques from mice treated with anti-CD40 antibodies.
Another study targeted signalling via CD40L and found that
deletion of CD40L in Apoe−/− mice (cd40l−/−Apoe−/− mice)
resulted in decreased plaque size and reduced numbers of
T cells and macrophages in atherosclerotic lesions com-
pared to Apoe−/− mice [54]. Similarly, Scho¨nbeck et al.
found that the CD40/CD40L pathway not only influences
the initial stages of atherosclerosis development but has
also an eﬀect in advanced disease. The authors showed that
treatment with anti-CD40L antibodies reduced the progres-
sion of already established atherosclerotic plaques in
Ldlr−/− mice [55]. An interesting finding was that blockade
of CD40/CD40L signalling resulted in atherosclerotic
plaques with a more stable phenotype, characterized by low
numbers of T lymphocytes and macrophages, suggesting
that the CD40/CD40L axis has important roles in plaque
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Table 2: TNF superfamily members and their role in atherosclerosis.
Receptor/ligand pair Experimental model Role in atherosclerosis Ref.
CD40/CD40L
Animal models
Mainly proatherogenic eﬀects (demonstrated by
administration of neutralising antibodies to CD40;
deletion of CD40L)
[53–55]
Human atherosclerosis
CD40 and CD40L are expressed in atherosclerotic
plaques
Increased levels of serum sCD40L in unstable angina;
correlate with poor prognosis
Polymorphisms in the CD40 gene associate with
unstable plaques and increased risk of ACS
[49, 61, 62]
OX40/OX40L
Animal models
Mainly proatherogenic eﬀects (demonstrated by
targeted deletion of OX40; administration of
neutralising antibodies to OX40L).
Human atherosclerosis
Polymorphisms in the genes for OX40 or OX40L
associate with myocardial infarction and CAD severity;
OX40 and OX40L upregulated in atherosclerotic tissue
or circulating immune cells; sOX40L serum levels
increased in ACS patients and associated with higher
risk of AMI
[83, 88, 90]
4-1BB/4-1BBL
Animal models
Promotes atherogenesis (demonstrated by
administration of agonist antibody anti-4-1BB;
deletion of 4-1BB).
[104, 107, 108]
Human atherosclerosis
4-1BB is expressed in atherosclerotic plaques; increased
levels on circulating immune cells; serum levels of
s4-1BB increased in ACS patients
[109, 110]
CD27/CD70 Human atherosclerosis
CD27 and CD70 are present in atherosclerotic plaques.
CD27+Treg cell subtype levels decreased in patients
with myocardial infarction
[122–124]
CD30/CD30L Human atherosclerosis Just one study available with inconclusive results [170]
HVEM/LIGHT Human atherosclerosis
HVEM and LIGHT detected in atherosclerotic plaques.
Elevated plasma levels of LIGHT in plasma of unstable
angina and ischemic (atherosclerotic) stroke patients
[148–151]
GITR/GITRL Human atherosclerosis
GITR and GITRL present in atherosclerotic plaques.
Decreased numbers of GITR+ Treg cells in
atherosclerotic lesions
[152, 153]
destabilisation [53–55]. A recent study which found that
the proatherogenic eﬀects of CD40L are independent
of CD40 as Ldlr−/− mice that were also deficient in CD40
(cd40−/−Ldlr−/− mice) showed no reduction in the formation
of atherosclerotic plaques compared to Ldlr−/− mice [56].
Furthermore, they proposed that CD40L eﬀects are mediated
by interaction with Mac-1 (CD11b/CD18), an integrin
receptor expressed on monocytes and macrophages [56].
These results clearly indicate that CD40/CD40L signalling
contributes to atherogenesis in murine models of the disease,
although the precise cell subsets that are involved in these
eﬀects are not completely defined. Indeed, some authors
proposed that CD40L expression on nonhaematopoietic cells
is important in atherogenesis [57, 58]. Bavendiek et al. [57]
found no diﬀerences in the size and cellular composition of
atherosclerotic plaques of irradiated Ldlr−/− mice that were
reconstituted with bone marrow from either Ldlr−/− mice or
Ldlr−/−cd40l−/− double deficient mice. Another study with
similar findings demonstrated that reconstitution of irradi-
ated Ldlr−/− mice with cd40l−/− bone marrow had no eﬀect
on the progression and phenotype of atherosclerotic lesions
when compared to wild type bone marrow [58]. It cannot
be excluded that, in the animal models analysed, some of
the antiatherogenic eﬀects of CD40/CD40L costimulatory
pathway blockade/deletion are mediated by alterations in the
expression and/or function of other costimulatory receptors/
molecules [59]. Another possible way in which CD40/CD40L
blockade could modulate atherogenesis is by changing the
balance between activated eﬀector T cells and regulatory T
cells. In a transplantation model it was found that CD40/
CD40L blockade not only inhibited the function of eﬀect-
or T cells but also enhanced the suppressive function
of CD4+CD25+ Treg cells [60]. Whether CD40/CD40L
blockade could alter the immuno-suppressive eﬀects of Treg
cells in atherosclerosis is not yet known.
Data from patients with atherosclerosis also suggest that
CD40L contributes to the pathogenesis of ACS and has prog-
nostic value (Table 2) [61, 62]. The levels of sCD40L, which is
released mainly from activated platelets and T lymphocytes,
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were elevated in the serum of unstable angina patients but
not in stable angina and healthy subjects [61]. Furthermore,
patients with unstable angina were found to have increased
percentages of both CD4+ and CD8+ T cells when compared
to stable angina patients and controls. As platelets have
been shown to be the main source of circulating sCD40L,
these cells could therefore account for most of the eﬀects
of sCD40L in atherogenesis [49]. Elevated sCD40L levels
were an independent predictor of recurrent cardiovascular
events after ACS and correlated with poor prognosis [62–64].
Of note, statins were found to dramatically downregulate
sCD40L levels in patients with familial hypercholesterolemia
[65]. Another indication that CD40 has proatherogenic
eﬀects is that polymorphisms in the CD40 gene were
found to associate with the presence of unstable coronary
atherosclerotic plaques and an increased risk of ACS [66, 67].
Given the important eﬀects of CD40/CD40L signalling
in atherosclerosis, therapeutic strategies that target this
pathway were thought to be beneficial in modulating the
inflammatory response in this disease. However, one obstacle
to clinical applications of targeting CD40/CD40L is the broad
expression of this receptor/ligand pair. In particular, con-
stitutive expression of CD40 on platelets and upregulation
of CD40L following platelet activation are responsible for
platelet activation and thrombosis [68]. Indeed, CD40 block-
ade was found to have prothrombotic eﬀects in humans that
prevent it from being used [49, 69]. Therefore, therapeutic
strategies that allow specific targeting of CD40/CD40L on
particular cell subsets (such as macrophages or T cells), but
not on platelets, need to be developed for successful clinical
applications in atherosclerosis.
6. OX40 and OX40L
The interaction between OX40 (also known as CD134) and
OX40L is critical for optimal generation of eﬀector T-cell
responses [70–72]. Ligation of OX40 elicits signalling path-
ways that sustained T-cell responses by prolonging clonal
expansion and enhanced cytokine secretion from eﬀector T
cells [73]. In addition, it upregulated the expression of anti-
apoptotic proteins of the Bcl-2 family (e.g., Bcl-2 and Bcl-
xL) and, by doing so, promoted the survival of activated T
lymphocytes [74]. Similar to other members of the TNFR
family, OX40 is not expressed on resting T cells (Table 1),
but can be induced both on CD4+ and CD8+ T cells after
TCR/CD3 triggering, with its levels reaching a peak approx-
imately 2-3 days following T-cell activation [70]. Moreover,
eﬀector/memory T cells rapidly reexpress OX40 after antigen
reencounter [75]. Of note, the expression of OX40 is not
restricted to conventional T cells as it was also found on Treg
cells, natural killer (NK) cells, NKT cells, and neutrophils
[76]. Recently, it has been shown that OX40/OX40L signals
have diﬀerent eﬀects on eﬀector T cells and Treg cells. While
OX40 promoted the expansion of eﬀector T cells, it blocked
the development and inhibited the suppressive function of
inducible Treg cells [77–80]. OX40L, the ligand for OX40,
is expressed in a variety of cell types such as APCs (e.g.,
DCs, macrophages, B cells), activated endothelial cells and
smooth muscle cells, NK cells, and mast cells [81, 82].
Importantly, activated T cells can also express OX40L [82],
which could ligate OX40 on other T cells and therefore
further amplify eﬀector T-cell immune responses. Activated
T cells expressing OX40 have been found at inflammatory
sites in experimental models and clinical specimens in sev-
eral inflammatory diseases, including rheumatoid arthritis
[25, 37]. Additionally, the levels of OX40 and OX40L are
significantly higher in inflamed versus healthy tissues [72].
In addition to its costimulatory roles, OX40 is thought to
regulate the T-cell migration and tissue infiltration through
its interaction with OX40L on endothelial cells [81].
Several studies support a role for OX40/OX40L interac-
tions in atherosclerosis and coronary artery disease (CAD)
(Table 2). In murine models of atherosclerosis, alterations
in the OX40/OX40L axis had profound eﬀects on disease
development. Indeed, mice with targeted deletion of OX40L
were found to have decreased atherosclerosis compared to
control mice, while overexpression of OX40L increased the
size of atherosclerotic plaques [83]. Moreover, administra-
tion of blocking antibodies to OX40L in Ldlr−/− mice reduc-
ed atherosclerosis [84]. This eﬀect was attributed to inhi-
bition of IL-4 production from Th2 cells, which favoured
the generation of protective IgM class anti-oxLDL antibodies
and inhibited the production of proatherogenic IgG class
antibodies. Another study demonstrated a reduction in
atherosclerosis in double knock-out Apoe−/−/ox40l−/− mice
compared to Apoe−/− mice [85]. The density of vasa vasorum
was reduced in OX40L-deficient animals, which suggested
that the OX40/OX40L system promotes the development
of atherosclerosis, at least in part, through vasa vasorum-
dependent neovascularization [85]. As mentioned previ-
ously, OX40/OX40L costimulatory signals were also found
to play a role in T-cell migration. Kotani et al. showed that
OX40L ligation can induce the production of the CC che-
mokine RANTES/CCL5 from endothelial cells, which could
mediate the adhesion and transmigration of T cells through
the endothelium at inflammatory sites [86]. In allograft
transplantation models, blockade of OX40/OX40L signalling
was found to enhance the survival of corneal allografts [87],
suggesting that targeting this pathway may provide a means
to tackle inflammatory disorders.
In humans, polymorphisms in the genes for OX40 or
OX40L were reported to associate with myocardial infarction
and the severity of CAD [83, 88]. In contrast, a recent study
on patients with carotid endarterectomy failed to find any
association between OX40L polymorphisms and the risk of
ischemic stroke [89]. In this study, OX40L was upregulated
in atherosclerotic lesions in comparison to control tissue
and was found mainly on macrophages infiltrating human
carotid atherosclerotic plaques. In further support of a role
for OX40/OX40L interactions in atherosclerosis, a recent
study described significantly higher expression of OX40 and
OX40L on circulating CD4+ T cells from ACS patients, when
compared to stable angina and controls [90]. We recently
found that CD4+CD28null T cells (a subset of T lymphocytes
that increases in frequency in patients with ACS compared to
stable angina and controls) had significantly higher levels of
OX40 than conventional CD4+CD28+ T lymphocytes [91].
Furthermore, inhibition of OX40 decreased the ability of
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CD4+CD28null T cells to produce inflammatory cytokines
(IFN-γ and TNF-α) and to release cytotoxic enzymes. Serum
levels of soluble OX40L (sOX40L) were increased in patients
with ACS and correlated with higher risk for severe coronary
events (i.e., myocardial infarction, recurrent angina, and
sudden death) [67, 90]. sOX40L levels were also shown to
correlate with carotid intima-media thickness and C-reactive
protein (CRP), while there was an indirect correlation with
IL-10, a potent immune-suppressive cytokine [90, 92]. Not-
ably, the levels of sOX40L decreased significantly in patients
with stroke that received statins compared to those on
routine medication [93]. In conclusion, these findings sug-
gest that OX40/OX40L costimulation enhances inflamma-
tion and promotes the development of atherosclerosis and
destabilisation of atherosclerotic plaques.
7. 4-1BB and 4-1BBL
4-1BB (CD137) is a potent and independent costimulatory
receptor of T cells. Similarly to OX40, 4-1BB is not expressed
by resting T cells, but induced on T cells hours to days
following antigen recognition [94] (Table 1). Its costimu-
latory activity is triggered upon binding to its ligand 4-
1BBL, present on APCs, and is responsible for promoting the
activation, survival, and function of eﬀector T cells [94]. In
addition to T cells, 4-1BB is widely expressed among the cells
of the immune system in particular monocytes, DCs, NK
and NKT cells, neutrophils, and eosinophils [94]. Similar-
ly, 4-1BBL is not restricted to APCs but was also found in
human primary T cells [95]. Of note, at sites of inflam-
mation, 4-1BBL can be expressed by nonimmune cells such
as cardiac myocytes in myocarditis and aortic tissue in
arteritis [96, 97]. Although 4-1BB costimulatory signals aug-
ment T-cell activation and survival, it was unexpectedly
found that 4-1BB-deficient T cells [98] and 4-1BB-deficient
myeloid progenitors are hyperproliferative [76]. In addition
to providing costimulatory signals for T-cell activation, 4-
1BB ligation by 4-1BBL can also trigger signalling pathways
in the cells that express the ligand 4-1BBL, which is also
called reverse signalling [99]. Monocytes, macrophages, and
DCs express 4-1BBL and reverse signalling has been shown
to promote their activation, migration, and survival [100].
Several investigations have shown that 4-1BB/4-1BBL
interactions contribute to the pathogenesis of various dis-
eases associated with chronic inflammation, including rheu-
matoid arthritis, allograft rejection, and cancer [101–103].
Recently, increasing evidence suggests that 4-1BB/4-1BBL
signals have proatherogenic roles (Table 2). A study from
Olofsson and colleagues clearly demonstrated that 4-1BB is
expressed in atherosclerotic plaques on T cells and endo-
thelium [104]. Moreover, the authors showed that Apoe−/−
mice treated with an agonist monoclonal antibody against
4-1BB developed increased atherosclerosis and that high
levels of infiltrating T cells and inflammatory cytokines were
detected in atherosclerotic plaques. The authors proposed
that interaction of 4-1BB costimulatory receptor (expressed
on T lymphocytes and endothelial cells) with 4-1BBL (on
macrophages) may enhance activation of T cells and endo-
thelial cells and ultimately contribute to plaque inflamma-
tion and disease aggravation. Of note, it was found that in
the hypoxic environment of tumours the expression of 4-
1BB is upregulated on endothelial cells [105]. Furthermore,
administration of agonist 4-1BB antibodies increased the
expression of adhesion molecules (i.e., ICAM-1, VCAM-1
and selectin) by endothelium and promoted entry of acti-
vated T cells into the tumour [105]. Hypoxia was also
described in human atherosclerotic lesions in areas rich in
macrophages and is believed to promote development of
advanced plaques by increasing inflammation and angiogen-
esis [106]. Therefore, it is possible that hypoxia is one of the
factors that is responsible for the expression of 4-1BB on the
endothelium in atherosclerotic plaques.
Further proof of the role of 4-1BB/4-1BBL sig-
nalling in atherosclerosis comes from Apoe−/−cd137−/− and
Ldlr−/−cd137−/− mice that showed reduced atherosclerosis
[107]. 4-1BB (CD137) deficiency in these double knock-out
mice decreased the production of inflammatory cytokines
such as IFN-γ, tumour necrosis factor-α (TNF-α), and mo-
nocyte chemoattractant protein-1 (MCP-1). Inhibition of
these inflammatory mediators may decrease leucocyte re-
cruitment and could therefore prevent plaque progression
and rupture [107]. Blockade of 4-1BB/4-1BBL pathway was
also shown to suppress neointimal hyperplasia in an ex-
perimental model of vascular injury [108].
Patients with ACS were found to have increased levels
of 4-1BB on circulating monocytes and elevated serum
soluble 4-1BB (s4-1BB) compared to SA patients and healthy
individuals [109, 110]. Moreover, 4-1BB levels correlated
with the presence of complex coronary stenosis [110]. In a
recent study, we showed that in ACS, 4-1BB was present in
higher levels on CD4+CD28null T cells than on conventional
CD4+CD28+ T lymphocytes [91]. Similarly to OX40, 4-
1BB blockade decreased IFN-γ and TNF-α secretion from
CD4+CD28null T cells and downregulated their cytotoxic
potential. An increase in s4-1BB was also found in patients
with multiple sclerosis, rheumatoid arthritis, and haemato-
logical malignancies [111–113], and it has been suggested
that it could reflect strong lymphocyte activation in vivo
[112]. This could be the case even in atherosclerosis, which is
often accompanied by activation and proliferation of T cells
in atherosclerotic plaques [11]. These findings suggest that
blockade of 4-1BB/4-1BBL axis could be used to modulate
progression of atherosclerotic lesions.
Experimental therapeutic approaches that block 4-
1BB/4-1BBL axis proved successful in the treatment of
several inflammatory diseases. Administration of a 4-1BB-
immunoglobulin fusion protein (4-1BB-Ig) attenuated ex-
perimental autoimmune myocarditis by decreasing the pro-
duction of inflammatory cytokines (IL-1, IL-6 and TNF-α)
[114]. 4-1BB-Ig was also shown to decrease the development
of graft arterial disease (GAD) in cardiac allografts [115].
In this model, blockade of 4-1BB inhibited infiltration with
T cells and the expression of inflammatory cytokines in the
grafted tissue. The authors proposed that modulation of the
4-1BB pathway may be a novel strategy to attenuate GAD
following heart transplantation [115]. In line with these
results, administration of agonistic antibodies for 4-1BB
accelerated rejection of corneal allografts [116]. Similarly,
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treatment with neutralising antibodies against 4-1BBL dur-
ing viral myocarditis decreased inflammation, T-cell infiltra-
tion, and overall improved long-term cardiac function [117].
In view of these positive results in experimental models,
the eﬀectiveness of 4-1BB-Ig fusion protein and anti-4-1BBL
neutralizing antibodies needs to be investigated in human
atherosclerosis.
8. CD27 and CD70
Another member of the costimulatory TNFR family that is
known to play a role in T-cell activation is CD27. In contrast
to OX40 and 4-1BB, naive T cells (both CD4+ and CD8+
T lymphocytes) constitutively express CD27 (Table 1) [118].
In addition, this receptor is also present on thymocytes,
B cells (especially memory B cells for which CD27 is a
marker), and NK cells [118, 119]. Its expression in activated
T cells increases following TCR/CD3 signalling and is then
downregulated with diﬀerentiation into eﬀector T cells. The
ligand for CD27 (CD70 or CD27L) is present on APCs and
B cells, and similar to OX40L and 4-1BBL was also found on
activated T cells [120, 121]. CD27 regulates the generation
of eﬀector T cells by promoting the proliferation and sur-
vival of T cells following activation both in primary and me-
mory immune responses. In addition, CD27 enhances the
diﬀerentiation of B cells into plasma cells and the production
of antibodies [119]. Moreover, interaction of CD27 on B cells
with CD70 on activated CD8+ T cells promotes the expan-
sion and survival of these T cells. However, sustained CD27–
CD70 interactions may cause immune pathology as it is
often the case in diseases associated with persistent immune
activation such as autoimmunity and chronic infections.
The role of CD27–CD70 signalling in atherosclerosis
is still under investigation (Table 2). CD27 and CD70 were
identified in T cells and macrophages in human athero-
sclerotic plaques [122]. In addition, increased levels of sol-
uble CD27 have been documented in other diseases driven
by persistent immune activation (autoimmunity and chronic
viral infection) [123]. Whether the same is true for patients
with atherosclerosis is currently unknown. When compared
to healthy individuals, patients with myocardial infarction
were found to have decreased levels of a Treg cell subset
characterized by high suppressive potential, which are iden-
tified by the expression of CD27 (CD27+ Treg cells) [124].
The authors suggested that CD27 expression is irreversibly
downregulated on Treg cells due to chronic activation of this
cell subset in the inflammatory context of atherosclerosis.
A recent study showed that CD70 transgenic Apoe−/− mice
were protected from atherosclerosis, possibly due to a predis-
position of circulating monocytes to apoptosis [125].
No data is currently available on targeting of CD27/CD70
in atherosclerosis. However, modulation of this costimula-
tory pathway was tested with success in autoimmunity and
transplantation. In an experimental autoimmune enceph-
alomyelitis model, anti-CD70 antibodies prevented disease
progression [126]. Surprisingly, this eﬀect was not mediated
by inhibition of T-cell activation but was attributed to a
decrease in the production of TNF-α. Similarly, blockade
of the CD27/CD70 pathway prolonged the survival of heart
allografts [127]. In this study, treatment with anti-CD70
antibodies reduced the generation of memory T cells and
resulted in decreased infiltration of allografts by eﬀector
CD4+ T cells. The authors also found that the percentage of
Treg cells was increased by anti-CD70 treatment, suggesting
that intragraft Treg cells could contribute to prolonged allo-
graft survival. One could envisage that a similar mechanism
of immunosuppression could be in place in atherosclerotic
plaques. Whether targeting the CD27/CD70 costimulatory
pathway could slow down atherosclerosis progression needs
to be tested in the future.
9. Novel TNFR Costimulatory Members
and Atherosclerosis
Other members of the TNFR family that have costimulatory
eﬀects on T cells are CD30, HVEM (herpes virus entry
mediator), and GITR (glucocorticoid-induced TNFR family
related gene). These relatively new TNFR family members
were found to have direct roles in regulation of T-cell re-
sponses following initial T-cell activation [25, 35]. CD30 is
found on activated T cells, B lymphocytes, eosinophils, and
NK cells (Table 1) [128]. Its ligand, CD30L, is present on B
cells and induced on T cells following activation [129, 130].
In primary T cells, CD30 ligation enhances proliferation
and cytokine production, similar to other costimulatory re-
ceptors [131, 132]. However, in lymphoma cell lines it was
found that CD30/CD30L signalling can trigger apoptosis
[133]. HVEM is expressed by resting T cells and APCs such as
DCs and monocytes [134, 135]. The main ligand of HVEM
is LIGHT, which is found on monocytes, DCs, NK cells, and
also activated CD4+ and CD8+ T lymphocytes [134, 135]. In
addition, HVEM was also found to interact with lympho-
toxin-α, BTLA (B and T lymphocyte attenuator), and CD160.
LIGHT and lymphotoxin-α promote T-cell activation, while
BTLA and CD160 have coinhibitory eﬀects [136]. It has
been suggested that HVEM is downregulated following ac-
tivation of T cells, although in vivo studies have found per-
sistent expression of both HVEM and LIGHT [137]. HVEM/
LIGHT interaction promotes T-cell activation and cytokine
production [138]. Resting T cells express low levels of
GITR, which is upregulated in activated CD4+ and CD8+
T lymphocytes [139, 140]. Of note, Treg cells constitutively
express high levels of GITR, which has been suggested to con-
tribute to their suppressive function [141, 142]. The ex-
pression of GITRL is mainly confined to APCs (e.g., macro-
phages, DCs, and B lymphocytes). GITR ligation enhances
the proliferation and viability of activated T cells. In addition,
GITR/GITRL upregulates the production of IL-2, IL-4, IFN-
γ, and IL-10 from T cells activated via TCR [139, 143].
CD30, HVEM and GITR have been implicated in various
autoimmune disorders (e.g., inflammatory bowel disease,
rheumatoid arthritis) [144], cancer [145, 146], and diabetes
[147].
Limited information is available on the involvement of
these new TNFR familymembers in atherosclerosis (Table 2).
Elevated levels of HVEM and LIGHT were found in the
aortas of Apoe−/− mice compared to wild type animals [148].
The cells expressing these molecules were macrophages and
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endothelial cells present in the atherosclerotic lesions. In the
human disease, HVEM and LIGHT have been detected in
atherosclerotic plaques, mainly in macrophages and foam
cells [149]. In the same study, in vitro HVEM ligation on a
myelomonocytic cell line was found to elicit the production
of matrix metalloproteinases (MMP-1, MMP-9, and MMP-
13). Furthermore, immunohistochemistry of carotid athero-
sclerotic plaques showed that HVEM and MMP staining
overlap [149]. The authors suggested that HVEM signalling
could promote plaque rupture via induction of MMPs.
Patients with unstable angina had significantly higher plasma
levels of LIGHT compared to controls [150]. Similarly,
elevated LIGHT plasma levels were found in patients
with ischemic (atherosclerotic) stroke [151]. GITR/GITRL
interactions have also been reported in atherosclerosis.
Indeed, GITR and its ligandwere identified in human athero-
sclerotic plaques mainly in lipid-rich macrophages [152].
Moreover, GITR-positive cells were observed in the intima in
all stages of atherosclerotic plaque development, while high-
risk plaques displayed focal accumulation of GITR-express-
ing cells. Of note, GITR staining overlapped with the staining
for the proinflammatory cytokine TNF-α and the matrix
metalloproteinase MMP-9 [152]. As GITR ligation triggered
the production of inflammatory cytokines and MMP-9 from
human and murine monocyte/macrophage cells lines, the
authors suggested that GITR has proatherogenic roles by
promoting macrophage activation and secretion of inflam-
matory cytokines and MMPs. A study that analysed the
frequency of Treg cells in atherosclerotic lesions found that
although GITR-positive Treg cells were present in the intima,
their number was reduced compared to those found in heal-
thy and inflamed skin [153]. Future research is required to
establish the precise roles of CD30, HVEM, and GITR in
atherosclerosis.
10. The Role of TRAFs in Atherosclerosis
TRAF proteins have been found to have key roles in the reg-
ulation of normal and pathogenic immune responses [154].
Recent studies also implicate TRAF proteins in atherosclero-
sis. All six types of mammalian TRAF members (TRAF1-6)
were expressed in both human and murine atherosclerotic
plaques. They were present mainly in endothelial cells and
macrophages in atherosclerotic lesions and are therefore be-
lieved to regulate the activation of proinflammatory path-
ways in these cells [155]. TRAF1 deficiency was shown to
attenuate atherogenesis in Ldlr−/− mice [156]. The authors
of this study suggested that impaired monocyte recruitment
into the vessel wall was the most likely underlying mech-
anism as the atherosclerotic plaques from TRAF1-deficient
animals has significantly fewer macrophages [156]. However,
other TRAF members were found to have opposite eﬀects on
the development and progression of atherosclerosis. Indeed,
TRAF5 deficiency was shown to accelerate atherogenesis
in Ldlr−/− mice possibly due to increased recruitment of
monocytes/macrophages into the vessel wall and enhanced
diﬀerentiation into foam cells [157]. TRAF6 interactions in
leukocytes were also shown to play a key role in athero-
sclerosis. Neointima formation and arterial remodelling was
reduced in mice with defects in CD40-TRAF6 [48]. Further-
more, specific disruption of CD40-TRAF6 in Apoe−/− mice
markedly reduced atherosclerosis and reduced the recruit-
ment of inflammatory macrophages into the arterial wall
[158]. Contrasting results were found when the role of
TRAF6 from haematopoietic cells was investigated in athero-
sclerosis. TRAF6 deficiency did not alter the formation of
atherosclerotic plaques in Ldlr−/− mice [159]. It is possible
that these divergent results suggest that the roles of TRAFs
in atherosclerosis may vary with the type of the stimulus,
receptors, or cell type involved in the propagation of the cos-
timulatory signal. Further investigations are required to clar-
ify the eﬀects of TRAFs in atherosclerosis.
11. Modulation of Costimulatory
Receptors of the TNFR Family
and Future Clinical Applications
in Atherosclerosis
Current therapies aimed at downregulating the immune
response in disorders associated with chronic inflammation
(autoimmunity, inflammatory diseases, organ transplanta-
tion) associate with an increased risk of infection due to sys-
temic immunosuppression. These eﬀects are caused by
nonspecific inhibition of all T cells and not only of those T
lymphocytes that are actively involved in the disease process.
A more eﬃcient approach would be to specifically target the
pathogenic T cells, while leaving untouched the rest of these
cells. In addition, if the same therapeutic agent would also ex-
pand Treg cells and/or boost their suppressive function, it
could further help to limit the inflammatory process and
control the disease. As described in the previous sections,
costimulatory receptors of the TNFR family are involved
in many disorders associated with chronic inflammation.
Therefore they represent promising targets for immunother-
apy, either to switch oﬀ the pathogenic immune response in
autoimmune or chronic inflammatory diseases by blockade
of costimulatory pathways, or to enhance adaptive immune
responses to combat tumours or chronic infections by active
induction of costimulatory signals. (Note: the applications
of TNFR costimulatory receptor modulation in cancer are
beyond the scope of this review and will not be discussed.)
One of the features of the TNFR costimulatory receptors
that makes them particularly suited for immunotherapy is
their preferential expression by pathogenic eﬀector T cells.
This is in particular true for OX40 and 4-1BB, which are
absent from naive/resting T cells and induced only following
activation of naive or memory T lymphocytes [70, 140].
Therefore, targeting these receptors could allow specific
elimination/inactivation of pathogenic T lymphocytes. In
addition, as OX40 regulates eﬀector T-cell migration and in-
filtration into inflamed tissues by interaction with OX40L
on endothelial cells [81, 160], blockade of OX40 could also
reduce tissue recruitment of pathogenic T cells. Another
feature that could prove useful in therapeutic applications is
the ability of several TNFR costimulatory receptors to pro-
mote survival of T lymphocytes [74]. Blockade of TNFR
could therefore enhance apoptosis of pathogenic T cells. As
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previously mentioned, the eﬃcacy of immunemodulation
in chronic inflammation could be dramatically increased if
downregulation of eﬀector T cells could be accompanied by
expansion of Treg cells and/or enhanced suppressive func-
tion. Both OX40 and 4-1BB were found to control the dif-
ferentiation and function of Treg cells, although the
information available is still conflicting. OX40 and 4-1BB
were found to suppress Foxp3 and IL-10 expression in CD4+
Treg cells, while enhancing the proliferation and survival of
both CD4+ and CD8+ Treg cells [77–80, 161]. The eﬀects
of OX40 and 4-1BB pathways on the function of Treg cells
are not fully understood, with reports of both inhibition
and potentiation of suppressive abilities [78, 80, 162, 163].
However, it is clear that targeting OX40 and 4-1BB could
modulate the expansion and/or suppressive function of
Treg cells. Of note, human Treg cells do not express OX40
[164], which should protect them from inhibition/deletion
by OX40 blockade.
An array of pharmacological tools has been developed
to modulate the interactions between TNFR costimulatory
receptors and their ligands that have yielded encouraging
results in preclinical studies and are now tested in patients
with asthma, autoimmunity, or cancer [25]. Blockade of
TNFR costimulatory signals can be achieved by adminis-
tration of neutralising monoclonal antibodies specific for
costimulatory receptors/ligands (e.g., neutralising antibodies
against OX40L, 4-1BBL, CD70) or TNFR-Ig fusion proteins
that work by binding to ligands and preventing their sub-
sequent interaction with costimulatory receptors (e.g.,
OX40-Ig, 4-1BB-Ig) [165–168]. These antibodies could be
further engineered to express a cellular toxin or to trigger
antibody-dependent cell-mediated cytotoxicity to enable
specific elimination of target cells. Agonistic antibodies that
stimulate TNFR signalling have also been generated to boost
anti-tumour immune responses (e.g., agonistic antibodies to
OX40, 4-1BB, and CD27). Surprisingly, it was found that 4-
1BB-specific agonistic antibodies have beneficial immuno-
suppressive eﬀects in various models of autoimmunity (e.g.,
lupus, arthritis, diabetes, encephalomyelitis, colitis) and in-
flammation (transplantation and asthma), possibly due to
expansion of CD4+ Treg cells and/or generation of CD8+
suppressive T cells [103, 169]. However, administration of
agonist antibodies specific for 4-1BB to Apoe−/− mice en-
hanced atherosclerosis [104], suggesting that these antibod-
ies could have diﬀerent eﬀects in various inflammatory con-
ditions. Whether cardiovascular events could be precipitated
by the administration of agonistic antibodies to 4-1BB (and
possibly OX40 and CD27) is not yet known. However, as
these antibodies would be preferentially administered to
patients with advanced carcinoma to enhance the anti-
tumoral immune response, the benefit of tumour control
may outweigh the risk of cardiovascular events. Modulation
of TRAF signalling could also provide a novel therapeutic
option for the treatment of atherosclerosis.
Several diﬃculties still hinder the design of clinical ther-
apeutic protocols based on modulation of TNFR costimula-
tory pathways. Some of these costimulatory receptors have
a more broad expression than OX40 and 4-1BB that could
lead to unwanted eﬀects. The best example is CD40 that is
constitutively expressed on platelets and triggers platelet ac-
tivation and thrombosis following ligation by CD40L (i.e.,
induced on activated platelets) [51, 68]. As expected, CD40
blockade was complicated by thrombotic events in humans
[49, 69]. Therapeutic strategies that enable cell-subset-spec-
ific targeting of costimulatory receptors/ligands are needed
for clinical applications. Another issue that complicates the
clinical translation of costimulatory receptor modulation is
that most of the data on the roles of TNF receptors and
ligands originate from studies done on animals and much
more limited information is available about the expression
and roles of these molecules in various stages of human dis-
ease. This limitation is further potentiated by the gap in the
knowledge of immunemechanisms that underlie human dis-
ease versus animal models of the disease. This is particularly
true in the case of atherosclerosis, where stark diﬀerences
exist between the pathogenic mechanisms of atherosclerosis
in animal models and the human disease. In addition, ap-
propriate models to dissect the mechanisms responsible for
atherosclerotic plaque rupture are still awaited. Another
complication arises from the complexity of the costimulatory
TNFR pathways, with several members regulating indepen-
dently or in concert the activation, proliferation, survival,
and function of eﬀector T cells. Future studies based on
animal models that better reproduce the evolution of hu-
man disease will hopefully clarify some of these issues and
will close the gap between experimental data and clinical ap-
plication of TNFR modulation.
12. Conclusion
Costimulatory receptors and ligands of the TNFR/TNF sup-
erfamily provide vital signals that promote the activation and
survival of T cells and guide the diﬀerentiation and function
of eﬀector/memory T cells. It is therefore not surprising that
recent research has shown that these receptors and ligands
have important roles in regulating the immune response
that underlies atherosclerosis. Importantly, data available so
far paint an optimistic picture for future clinical applications
of TNFR modulation. In particular, OX40/OX40L and
4-1BB/4-1BBL are promising candidates for immunemod-
ulation in atherosclerosis, with CD40/CD40L being marred
by thromboembolic complications. The main advantages
of immunemodulation of OX40/OX40L or 4-1BB/4-1BBL
are specific targeting of pathogenic eﬀector T cells without
generalised immunosuppression of T cells; inhibition of both
proliferation and survival of activated T cells; concomitant
induction of Treg cells and/or amplification of their sup-
pressive function. However, future research is still required
to clarify some points such as patient selection (responses
may be better in patients that have enhanced levels of TNFR
costimulatory receptors); which costimulatory receptor or
combination of receptors is better to modulate the disease;
timing and dosing of pharmacological reagents; which
therapeutic reagent (neutralising antibodies, depleting anti-
bodies, TNFR-Ig-fusion proteins, TRAF inhibitors) induces
the best clinical eﬀects with minimum unwanted reactions.
Hopefully, we are not very far from the day when TNFR
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targeting will lead to (co-)stimulating results in the clinical
setting.
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